Alissa Robbins
Overview
Explore the profile of Alissa Robbins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis M, Coury J, Sanchez V, Kenzie E, Larson J, Barnes C, et al.
BMC Health Serv Res
. 2024 Nov;
24(1):1384.
PMID: 39533319
Background: Implementation of screening brief intervention and referral to treatment (SBIRT) and medication-assisted treatment for alcohol use disorder (MAUD) remains low in primary care. ANTECEDENT (Partnerships to Enhance Alcohol Screening,...
2.
Bendapudi P, Nazeen S, Ryu J, Soylemez O, Robbins A, Rouaisnel B, et al.
Blood
. 2023 Dec;
143(11):1032-1044.
PMID: 38096369
Extreme disease phenotypes can provide key insights into the pathophysiology of common conditions, but studying such cases is challenging due to their rarity and the limited statistical power of existing...
3.
Singh A, Sanchez V, Kenzie E, Sullivan E, McCormack J, Larson J, et al.
PLoS One
. 2022 Jun;
17(6):e0269635.
PMID: 35763485
Background: Unhealthy alcohol use (UAU) is a leading cause of morbidity and mortality in the United States, contributing to 95,000 deaths annually. When offered in primary care, screening, brief intervention,...
4.
Policheni A, Teh C, Robbins A, Tuzlak S, Strasser A, Gray D
Proc Natl Acad Sci U S A
. 2022 Apr;
119(15):e2120149119.
PMID: 35394861
Immunological tolerance is established and maintained by a diverse array of safeguards that work together to protect against autoimmunity. Despite the identification of numerous tolerogenic processes, the basis for cooperation...
5.
Bendapudi P, Robbins A, LeBoeuf N, Pozdnyakova O, Bhatt A, Duke F, et al.
Blood Adv
. 2018 Nov;
2(21):2917-2921.
PMID: 30396911
No abstract available.
6.
Khaw S, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva R, et al.
Blood
. 2016 Jun;
128(10):1382-95.
PMID: 27343252
The clinical success of the BCL-2-selective BH3-mimetic venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potential of targeting the BCL-2-regulated apoptotic pathway in previously untreatable lymphoid...
7.
Richmond J, Robbins A, Evans K, Beck D, Kurmasheva R, Billups C, et al.
Cancer Res
. 2016 Jun;
76(15):4579-91.
PMID: 27302164
Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of...
8.
Churchman M, Evans K, Richmond J, Robbins A, Jones L, Shapiro I, et al.
JCI Insight
. 2016 Apr;
1(4).
PMID: 27123491
BCR-ABL1 B progenitor acute lymphoblastic leukemia (Ph B-ALL) is an aggressive disease that frequently responds poorly to currently available therapies. Alterations in , which encodes the lymphoid transcription factor Ikaros,...
9.
Maude S, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al.
Blood
. 2015 Feb;
125(11):1759-67.
PMID: 25645356
Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well as a high rate of...
10.
Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, et al.
Clin Cancer Res
. 2015 Jan;
21(6):1395-405.
PMID: 25573381
Purpose: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience shorter remission...